YF-VAX 1 dose vials
Ended Awarded Last action
- Contract number
- SPE2DR26FRFJ8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,259
Award facts
- Contract value 100% obligated
- $1,259.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,259.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of YF-VAX (yellow fever vaccine) in one-dose vial format. The award, issued on January 7, 2026, with an ultimate completion date of January 29, 2026, is structured as a firm fixed-price delivery order with no set-aside designation, indicating the contractor's ability to compete effectively in unrestricted federal pharmaceutical procurement. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to supply pharmaceutical products to military healthcare facilities worldwide.
DMS Pharmaceutical Group maintains a single-award IDC under the PPV-G GEN V program with a ceiling value of $499,999,999 and a completion date of December 31, 2036, positioning the company as a critical regional prime vendor contractor for the Department of Defense pharmaceutical supply chain. The company's product portfolio encompasses a comprehensive range of medications including branded and generic prescription drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables. As a registered System for Award Management vendor since July 2001, DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and consistent performance across multiple therapeutic categories, supporting DOD medical operations with reliable pharmaceutical supply capabilities.
Quick answers
Who was awarded contract SPE2DR26FRFJ8?
SPE2DR26FRFJ8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FRFJ8 worth?
The government has obligated $1,259 on SPE2DR26FRFJ8.
Is contract SPE2DR26FRFJ8 an order under another contract?
Yes. SPE2DR26FRFJ8 is a delivery order under SPE2DR25D9203, an indefinite delivery contract.
Was contract SPE2DR26FRFJ8 competed?
The extent of competition for SPE2DR26FRFJ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award